Heinzerling, L M <br/><br/>
Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma.  [electronic resource] 

 -  Cancer  Oct 2000 
 - 1835-44 p.  digital 
<br/><br/> Publication Type: Case Reports; Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>0008-543X 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Agents--administration & dosage<br/>Female<br/>Humans<br/>Infusions, Intravenous<br/>Lymphoma, B-Cell--drug therapy<br/>Lymphoma, Large B-Cell, Diffuse--drug therapy<br/>Male<br/>Middle Aged<br/>Rituximab<br/>Skin Neoplasms--drug therapy<br/>Treatment Outcome